PhRMApedia Press Room
PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases. PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.
Washington, D.C. (May 21, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on the House Energy and Commerce Committee’s passage of 21st Century Cures legislation:
WASHINGTON (May 15, 2015) – PhRMA President and Chief Executive Officer John J. Castellani announced today that Executive Vice President, Administration, and Chief Financial Officer Del Persinger will retire effective May 31, concluding 18-1/2 years leading the organization’s finance and operations functions. Paul A. Aines, currently Chief Financial Officer and Senior Director of the American Society of Clinical Oncology (ASCO), will succeed Persinger. Aines will start at PhRMA on June 15.
Data Released Today is Misleading
WASHINGTON, D.C. (April 30, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO John J. Castellani released the following statement on today’s Medicare Part D data release:
“PhRMA supports efforts to increase transparency in health care costs, which can help support improved health care quality and efficiency. However, the Medicare Part D cost data released today are misleading and an inaccurate representation of actual Medicare Part D spending.
WASHINGTON, D.C. (April 30, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President Jay Taylor issued the following statement today:
America’s innovative biopharmaceutical manufacturers and the more than 810,000 women and men they employ depend on strong intellectual property protection and enforcement to bring new medicines to patients who need them. Today, more than 7,000 medicines are in development across the country and around the world.
WASHINGTON, D.C. (April 29, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Robert Zirkelbach issued the following statement:
“The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the efforts of Senate Judiciary Committee Chairman Chuck Grassley (R-IA), Ranking Member Patrick Leahy (D-VT), Senator John Cornyn (R-TX), and Senator Chuck Schumer (D-NY) in introducing legislation today to address abusive patent litigation. While the Senate legislation is an improvement over the House version, there continue to be issues of concern that intellectual property holders have raised, and we look forward to working with Senators to address those concerns.
Washington, D.C. (April 29, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on the newly released 21st Century Cures draft:
“PhRMA applauds the work of Chairman Upton, Congresswoman DeGette, Ranking Member Pallone and members of the Committee for their tireless work to issue the latest Cures draft after a year of working with stakeholders, patient groups and others to accelerate the discovery, development and delivery of new medicines for patients. We strongly supported the House Energy and Commerce Committee’s bipartisan effort to develop this draft and were pleased to provide feedback during the process.
PhRMA member companies invested an estimated $51.2 billion last year in the research and development (R&D) of new innovative treatments and cures. The figure represents the majority of all biopharmaceutical R&D spending – both public and private – in the United States.
Award Honors Extraordinary Efforts in Policy Advocacy and Community Service
Washington, D.C. (April 17, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions” for their extraordinary efforts in policy advocacy and community service.
Biogen CEO George A. Scangos and Johnson & Johnson Worldwide Chairman for Pharmaceuticals Joaquin Duato Assume New Posts ; Castellani Announces Retirement
Washington, D.C. (April 16, 2015) — Today, Kenneth C. Frazier, chairman and chief executive officer (CEO) of Merck & Co., Inc., was elected chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA). At today’s Board meeting, PhRMA’s president and CEO John J. Castellani announced that he will be retiring effective January 1, 2016.
New Officers Elected to PhRMA Board
Washington, D.C. (April 15, 2015) — The Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation has awarded four research grants as part of its Young Investigator Adherence Grant Program.
Established in 2012, the Young Investigator Adherence Grant Program was created by the PhRMA Foundation to support research conducted by predoctoral candidates, postdoctoral fellows, and junior faculty to advance knowledge of innovative and effective approaches to improve medication adherence.
Washington, D.C. (April 7, 2015) —The Partnership for Prescription Assistance (PPA), a program sponsored by America’s biopharmaceutical research companies to connect uninsured or underinsured Americans to programs that provide prescription medicines for free or nearly free, is celebrating its 10th anniversary this week. Since the program’s launch in April 2005, PPA has connected nearly 9.5 million Americans to public and private assistance programs.
Despite more Americans having insurance, barriers to accessing needed medicines still exist, underscoring the importance of PPA’s platform to educate and empower patients and caregivers to obtain information about their prescription assistance options.
PhRMA supports a science-based, transparent implementation of the BPCIA biosimilars pathway.
Washington, D.C. (March 3, 2015) — Today, the Partnership for Prescription Assistance (PPA), a nationwide effort sponsored by America’s biopharmaceutical research companies, unveiled a redesigned website with new features and functionality to provide patients and caregivers with faster, easier access to information on more than 475 public and private patient assistance programs.
Visit www.FromHopetoCures.org to learn more about the value medicines provide to patients, society and our economy
Washington, D.C. – Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies.
Washington, D.C. (February 25, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President of Scientific and Regulatory Affairs Dr. Bill Chin issued the following statement today in support of legislation to prevent sequestration of prescription drug user fees:
“PhRMA strongly supports the FDA Safety Over Sequestration Act, which would exempt future Food and Drug Administration’s (FDA) user fees from sequestration. We commend Representatives Leonard Lance (R-NJ) and Anna Eshoo (D-CA) for their continued leadership on this critical issue.